By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemoproteomics firm Cellzome today announced a collaboration with Pfizer to study epigenetic mechanisms involved in stem cell differentiation.

Cellzome will use its Episphere platform to characterize epigenetic changes while Pfizer's Pain & Sensory Disorders and Regenerative Medicine unit, Neusentis, will provide expertise in stem-cell handling and regenerative medicine.

Financial and other terms were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.